07/13/2020 | Press release | Distributed by Public on 07/13/2020 08:37
Created with the user experience in mind, the site is easy to navigate and it is easy to find the information needed. We hope to provide our partners with the most accurate, up-to-date information and share our knowledge and expertise in the field of Neuromuscular monitoring and preventable complications. The goal with this website is to provide customers with an easy way to learn about the optimization of patient management in patients receiving neuromuscular blocking agents (NMBAs).
Senzime's TetraGraph neuromuscular monitor is a unique digital system designed to address the needs of perioperative monitoring of physiologic data in surgical patients receiving general anesthesia and muscle relaxation using neuromuscular blocking drugs (NMBAs). The TetraGraph stimulates a peripheral nerve and measures, analyzes and displays in real-time the muscle function in surgical patients who receive NMBAs as part of their general anesthetic.
For further information, please contact:
Pia Renaudin, CEO of Senzime AB
Tel: +46 (0)70-813 34 17, email: [email protected]
TO THE EDITORS
Senzime develops and markets CE- and FDA cleared patient monitoring systems driven by unique algorithms and sensors to closely monitor patients under anesthesia. TetraGraph is a system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow guidelines and drug recommendations, TetraGraph can contribute to shorten hospital stays and lower healthcare costs. The vision is a world without anesthesia related complications, where everyone wakes up safely after surgery. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq
First North Growth Market (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, [email protected]is Certified Adviser for Senzime. www.senzime.com